Filing Details

Accession Number:
0001140361-22-027528
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-07-29 21:30:31
Reporting Period:
2022-07-27
Accepted Time:
2022-07-29 21:30:31
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1559053 Prothena Corp Public Ltd Co PRTA Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1564380 G. Gene Kinney C/O Prothena Biosciences Inc
331 Oyster Point Boulevard
South San Francisco CA 94080
President And Ceo No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares, Par Value $0.01 Per Share Acquisiton 2022-07-27 376 $6.41 13,169 No 4 M Direct
Ordinary Shares, Par Value $0.01 Per Share Disposition 2022-07-27 376 $32.00 12,793 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Stock Option (Right to Buy) Disposition 2022-07-27 376 $0.00 376 $6.41
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
98,698 2023-01-29 No 4 M Direct
Footnotes
  1. The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
  2. The option was granted on January 29, 2013 and all shares subject to the option were fully vested and exercisable. The option will expire in approximately six months and be forfeited to the extent it is not exercised on or prior to January 29, 2023.
  3. The Reporting Person holds options that give him the right to acquire an aggregate of 2,103,398 shares at exercises prices ranging from $6.41 to $32.45, of which 1,571,938 are currently exercisable, and 531,460 are currently unexercisable but vest over time, subject to the Reporting Person's continued employment with the Issuer on each applicable vesting date of each option award.